T helper 17 cells and interleukin-17 immunity in type 1 diabetes:From pathophysiology to targeted immunotherapies  

作　　者：Georgi Vasilev Maria Kokudeva Elina Siliogka Nathalia Padilla Russka Shumnalieva David Della-Morte Camillo Ricordi Antoaneta Mihova Marco Infante Tsvetelina Velikova 

机构地区：[1]Clinic of Neurology and Department of Emergency Medicine,UMHAT"Sv.Georgi",Plovdiv 4000,Bulgaria [2]Medical Faculty,Sofia University St.Kliment Ohridski,Sofia 1407,Bulgaria [3]Department of Pharmacology and Toxicology,Faculty of Pharmacy,Medical University of Sofia,Sofia 1000,Bulgaria [4]Faculty of Medicine,National and Kapodistrian University of Athens,Athens 11527,Attikí,Greece [5]Diabetes Research Institute,University of Miami Miller School of Medicine,Miami,FL 33136,United States [6]Department of Rheumatology,Clinic of Rheumatology,University Hospital"St.Anna",Medical University-Sofia,Sofia 1612,Bulgaria [7]Department of Biomedicine and Prevention,Section of Clinical Nutrition and Nutrigenomics,University of Rome Tor Vergata,Rome 00133,Italy [8]Department of Immunology,SMDL Ramus,Sofia 1527,Bulgaria [9]Section of Diabetes&Metabolic Disorders,UniCamillus,Saint Camillus International University of Health Sciences,Rome 00131,Italy

出　　处：《World Journal of Diabetes》2025年第4期48-61,共14页世界糖尿病杂志(英文)

基　　金：Supported by the European Union-NextGenerationEU,through the National Recovery and Resilience Plan of the Republic of Bulgaria,No.BG-RRP-2.004-0008.

摘　　要：Type 1 diabetes(T1D)is a chronic organ-specific autoimmune disorder characterized by a progressive loss of the insulin-secreting pancreatic beta cells,which ultimately results in insulinopenia,hyperglycemia and lifelong need for exogenous insulin therapy.In the pathophysiological landscape of T1D,T helper 17 cells(Th17 cells)and their hallmark cytokine,interleukin(IL)-17,play pivotal roles from disease onset to disease progression.In this narrative mini-review,we discuss the dynamic interplay between Th17 cells and IL-17 in the context of T1D,providing insights into the underlying immunologic mechanisms contributing to the IL-17-immunity-mediated pancreatic beta-cell destruction.Furthermore,we summarized the main animal and clinical studies that investigated Th17-and IL-17-targeted interventions as promising immunotherapies able to alter the natural history of T1D.

关 键 词：Type 1 diabetes T helper 17 cells INTERLEUKIN-17 T helper 1 cells Regulatory T cells Anti-interleukin-17 treatment Th17-targeted treatment 

分 类 号：R587.1[医药卫生—内分泌] R186[医药卫生—内科学]